Long-term budesonide orodispersible tablets effectively maintained remission in patients with eosinophilic esophagitis and demonstrated a favorable safety profile.
The total market size of eosinophilic esophagitis in 2023 was approximately USD 1.80 trillion in the 7MM, which is expected to grow during the forecast period (2020-2034). Among EU4 and the UK, ...
A recent novel study published in the New England Journal of Medicine found that Depemokimab can reduce asthma exacerbations in patients with the eosinophilic phenotype. Improperly controlled asthma ...
Emphysema did not significantly affect the response to systemic therapy in patients with severe asthma, according to a recent retrospective study. Early improvement was linked to lower baseline FEV1 ...
Daily or Twice Daily Treatment with Topical Steroids Results in Similar Responses in Eosinophilic Esophagitis. In Clinical Gastroenterology ... Metoprolol Safer Beta Blocker for Asthma Patients, ...
Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
Macrolides reduce exacerbations when added to inhaled therapy in severe asthma. However, there is little published evidence for effectiveness in patients treated with biologics. We conducted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback